Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (2020 - 2025)

Foghorn Therapeutics has reported Shares Outstanding over the past 6 years, most recently at $56.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $56.7 million for Q4 2025, up 1.91% from a year ago — trailing twelve months through Dec 2025 was $56.7 million (up 1.91% YoY), and the annual figure for FY2025 was $56.7 million, up 1.91%.
  • Shares Outstanding for Q4 2025 was $56.7 million at Foghorn Therapeutics, roughly flat from $56.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for FHTX hit a ceiling of $56.7 million in Q4 2025 and a floor of $36.8 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $42.0 million (2023), compared with a mean of $46.0 million.
  • Biggest five-year swings in Shares Outstanding: decreased 8.81% in 2021 and later surged 32.2% in 2024.
  • Foghorn Therapeutics' Shares Outstanding stood at $41.3 million in 2021, then grew by 1.22% to $41.8 million in 2022, then grew by 1.14% to $42.3 million in 2023, then surged by 31.48% to $55.6 million in 2024, then increased by 1.91% to $56.7 million in 2025.
  • The last three reported values for Shares Outstanding were $56.7 million (Q4 2025), $56.5 million (Q3 2025), and $55.8 million (Q2 2025) per Business Quant data.